© 2024 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY · WNPR
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Cancer Answers is hosted by Dr. Anees Chagpar, Associate Professor of Surgical Oncology and Director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital, and Dr. Francine Foss, Professor of Medical Oncology. The show features a guest cancer specialist who will share the most recent advances in cancer therapy and respond to listeners questions. Myths, facts and advances in cancer diagnosis and treatment are discussed, with a different focus eachweek. Nationally acclaimed specialists in various types of cancer research, diagnosis, and treatment discuss common misconceptions about the disease and respond to questions from the community.Listeners can submit questions to be answered on the program at canceranswers@yale.edu or by leaving a message at (888) 234-4YCC. As a resource, archived programs from 2006 through the present are available in both audio and written versions on the Yale Cancer Center website.

U.S. Journalist With Ebola Flown To Nebraska For Treatment

An ambulance transports Ashoka Mukpo, who contracted Ebola while working in Liberia, to The Nebraska Medical Center's specialized isolation unit on Monday in Omaha.
Dave Weaver
/
AP
An ambulance transports Ashoka Mukpo, who contracted Ebola while working in Liberia, to The Nebraska Medical Center's specialized isolation unit on Monday in Omaha.

Updated at 10:20 a.m. ET

The condition of a man infected with the Ebola virus who is undergoing treatment in Dallas is "fighting for his life," doctors say, as another patient with the disease has arrived in Nebraska to receive care.

Thomas Eric Duncan, in isolation at Texas Health Presbyterian Hospital, became ill after arriving from the West African country of Liberia two weeks ago.

The head of the Centers for Disease Control in Atlanta, Dr. Thomas Frieden, told CNN on Sunday that Duncan was "fighting for his life" but said he was not receiving any experimental treatments.

Reuters says:

"Frieden, who is slated to brief President Barack Obama on Monday, said doses of the experimental medicine ZMapp were 'all gone' and that the drug, produced by San Diego-based Mapp Biopharmaceutical, is 'not going to be available anytime soon.'

"A second experimental drug, made by Canada's Tekmira Pharmaceuticals Corp, 'can be quite difficult for patients to take,' he said, adding that the doctor and the patient's family would decide whether to use the drug."

NPR's Rob Stein reports, however, that Duncan is receiving a different experimental drug, brincidofovir. The Associated Press describes it as an oral medication being tested by a North Carolina company for use against several other types of viruses.

Meanwhile, freelance photographer Ashoka Mukpo, who also contracted Ebola in Liberia, is being moved to The Nebraska Medical Center in Omaha, where he will be treated inside a special isolation unit.

NBCNews reports that Mukpo, 33, departed Liberia on a specially equipped airplane and that the aircraft would make a brief refueling stop in Bangor, Maine, before landing in Omaha.

Although others, like Mukpo, have arrived in the U.S. for treatment after testing positive for Ebola, Duncan is the only patient to be diagnosed on U.S. soil.

Meanwhile, the Pentagon says that 1,600 soldiers from the U.S. Army 101st Airborne Division are being deployed to Liberia beginning next week.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Scott Neuman is a reporter and editor, working mainly on breaking news for NPR's digital and radio platforms.

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Related Content